Company: REVB
Filing Date: 2025-09-15
Form Type: 8-K
Source: 0001193125-25-203750
Chunk: 0

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-09-15
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On September 10, 2025, Revelation Biosciences, Inc. (the “ Company”) entered into warrant exercise inducement offer letters (the “ Inducement Letters”) with certain holders (the “ Holders”) of 13,065,000 existing Class H Common Stock Warrants exercisable for an aggregate of 4,355,000 shares of its common stock (collectively, the “ Existing Warrants”), to exercise their warrants at an exercise price of $2.20 per share, in exchange for the Company’s agreement to issue 13,065,000 new common stock warrants (the “ Class I Common Stock Warrants”) as described below. The aggregate gross proceeds from the exercise of the Existing Warrants is approximately $9.6 million, before deducting financial advisory fees. The issuance of the Class I Common Stock Warrants was structured as an at-market transaction under Nasdaq rules.

The Company intends to use the net proceeds from the warrant exercises in connection with its clinical development plans and to fund working capital and general corporate purposes.

The shares of common stock issuable upon exercise of the Existing Warrants are registered for issuance pursuant to a registration statement on Form S-1 (File No. 333-287423), which was declared effective by the Securities and Exchange Commission (the “ SEC”) on May 28, 2025.

In consideration for the immediate exercise of the Existing Warrants for cash, the exercising Holders received the Class I Common Stock Warrants in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act”). The Class I Common Stock Warrants have an exercise price of $2.20 per share, are not exercisable until stockholder approval, and will be exercisable for five years from the date of stockholder approval.

The Class I Common Stock Warrants and the shares of common stock underlying the Class I Common Stock Warrants offered in the private placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the SEC within twenty days of the closing to register the resale of the shares of common stock underlying